関連する実験動画
Updated: Jan 3, 2026

06:59
Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
39.9K
GPR146欠乏症 高コレステロール血症と動脈硬化症から保護する
Haojie Yu1, Antoine Rimbert2, Alice E Palmer3
1Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, MA 02215, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.
Cell
|November 29, 2019
まとめ
孤児Gタンパク質結合受容体146 (GPR146) は,ERK経路を活性化して,非常に低密度の脂質タンパク質分泌に影響を与え,コレステロール代謝を調節する. GPR146の抑制は血コレステロールを大幅に低下させ,動脈硬化症を減少させます.
科学分野:
- 生物化学
- 分子生物学
- 心血管研究
背景:
- 遺伝学的な研究は多くの遺伝子を 血脂レベルと関連付けていますが,その正確な機能は不明です.
- 脂質代謝を調節する分子メカニズムを理解することは 心血管疾患の治療に不可欠です
研究 の 目的:
- 脂質代謝における孤児Gタンパク質結合受容体146 (GPR146) の生理学的および分子的機能を明らかにする.
- 肝臓の非常に低密度脂質タンパク質 (VLDL) の分泌と全身のコレステロールのレベルを調節するGPR146の役割を調査する.
主な方法:
- 細胞外信号調節キナーゼ (ERK) 信号伝達経路を通じて,ステロール調節要素結合タンパク質2 (SREBP2) の活性に対するGPR146の影響を調査した.
- GPR146欠乏症のマウス (野生型とLDL受容体欠乏症の両方) を用いて,血脂質プロファイルと動脈硬化病変の発達を評価した.
主要な成果:
- GPR146はERKシグナル伝達を通じてSREBP2の活性を促進し,肝臓のVLDL分泌と循環中のLDL- Cおよびトリグリセリドのレベルに影響を与えます.
- GPR146欠乏症は,野生型およびLDLR欠乏症のマウスの血コレステロールを著しく低下させた.
- GPR146の減少は,LDLR欠乏したマウスの大動脈動脈硬化病変を有意に減少させた (雄の90%と雌の70%).
結論:
- GPR146 / ERK軸は,全身のコレステロール代謝の重要な規制役割を果たしています.
- GPR146を阻害することは,血コレステロールを低下させ,動脈硬化症を緩和するための潜在的な治療戦略です.
関連する概念動画
Cholesterol: Significance and Regulation
1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.2K
Atherosclerosis III: Management
285
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
285
GPCR Desensitization
7.8K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.8K
Atherosclerosis I: Introduction
716
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
716

